Zolgensma denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for zolgensma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Issue a "Not FDA-Approved" Denial for Zolgensma

Zolgensma (onasemnogene abeparvovec) has received FDA approval for spinal muscular atrophy (SMA). A "not FDA-approved" denial from UnitedHealthcare therefore almost always reflects one of three situations: (1) the claim was submitted in a way that did not make FDA approval status clear; (2) the insurer's policy restricts coverage to a narrower population than the full FDA-approved label, and the patient falls outside that narrower group in the plan's view; or (3) an administrative or coding error caused the denial to be generated incorrectly.

This type of denial is directly rebuttal-able by producing the FDA approval documentation. Identify which scenario applies before drafting your appeal, because the strategy differs: a coding error is resolved administratively, while a population-restriction dispute requires a clinical argument.

## Your Appeal Rights

• Internal appeal: File within the deadline stated on the denial notice (commonly 180 days). Under ERISA §503, you are entitled to a full-and-fair review, including access to every clinical criterion and guideline the plan relied upon.
• External review (ACA §2719): After an adverse internal decision, you may request independent external review. The standard window extends up to four months from the final internal denial. For urgent situations, an expedited external review must be completed within 72 hours.
• State regulator: For fully-insured plans, your state's insurance commissioner can accept complaints when an insurer incorrectly labels an FDA-approved therapy as unapproved.

## Documentation to Gather

1. FDA approval documentation — download and attach the current FDA label and approval letter directly from the FDA website (fda.gov). This is the single most important document for this denial type. 2. Confirmed SMA diagnosis — genetic test report with SMN1 and SMN2 copy number analysis, signed by the ordering clinician. 3. Clinical records — neurologist notes documenting SMA type, symptom onset, disease progression, and current functional status. 4. Prescriber letter — the treating neurologist should explicitly confirm FDA-approved status and that the specific indication falls within the approved label. 5. Claim/coding review — ask the billing team to verify the submitted diagnosis and procedure codes against what UHC requires for Zolgensma claims; a coding correction may resolve the denial without a full appeal.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's published coverage policy for Zolgensma. Compare each stated criterion to the chart and the FDA label:

| Denial Basis / Policy Criterion | Response + Supporting Document | |---|---| | FDA approval status | FDA label + approval letter (attached) | | Confirmed SMA diagnosis | Genetic lab report, [date] | | Patient population per UHC policy vs. FDA label | Neurologist letter addressing any gap | | Correct procedure/diagnosis coding | Billing team code review |

The appeal cover letter should open by stating clearly: "Zolgensma received FDA approval on [date per the FDA label] for [the approved indication per the label]." Attach the FDA documentation as exhibit A and let the reviewer see the approval in the first paragraph. This framing immediately distinguishes the case from a genuine experimental-therapy dispute.